- Healthcare: We highlight our top Healthcare pick for this month, namely Evgen Pharma* (EVG.L, BUY, PT 79p). Evgen’s core technology allows for the production of a stable version of sulforaphane, a potential treatment for various conditions, including several cancers and neurological disorders. To date, despite considerable evidence supporting sulforaphane’s therapeutic properties, issues surrounding the drug’s stability, storage and delivery have hindered its development. Thanks to Evgen’s patented Sulforadex® technology platform, the company is well positioned to unlock the medical and commercial potential of this promising drug. Our 79p Target Price indicates substantial upside to the group’s current c. 30p share price
Northland Capital Partners Limited (‘Northland’ or ‘the Firm’) is authorised and regulated by the Financial Conduct Authority (‘FCA’) and is a member of the London Stock Exchange.
The Firm’s research reports/communications are non-independent ‘marketing communications’, such term as defined in the Rules of the FCA. Marketing communications are not prepared in accordance with the FCA’s Rules on independent investment research and are not subject to any prohibition on dealing ahead of their dissemination. Northland’s ‘Conflicts Management Policy’ includes details of potential conflicts concerning its research activities and is available on its website: www.northlandcp.co.uk. Company specific conflicts disclosures are included in each relevant communication made by Northland. The Firm and/or its officers, directors and employees may have, or take positions in securities of companies mentioned in its research communications (or in any related investment) and may from time to time dispose of any such positions.
Northland’s research communications are not intended for and should not be relied upon by ‘Retail Clients’ (such term as defined in the FCA Rules). The Firm’s research communications (‘communications’) are provided for information purposes only and on the understanding that Northland is not acting in a fiduciary capacity, nor is it making a personal recommendation and should not be regarded as an offer or solicitation to buy or sell any security or other financial instrument. Northland’s communications have no regard to the specific investment objectives, financial situation and needs of any specific person or entity. If in any doubt, investors should seek advice from a suitable investment advisor. The Firm’s communications are based on materials and sources that it believes to be reliable; however, they are not independently verified. No representation or warranty either expressed or implied, is made and no responsibility is accepted by Northland as to the accuracy or completeness of any information contained in its research communications, nor should it be relied on as such. Opinions and estimates in its research communications are subject to change without notice and Northland is under no obligation to update such opinions and estimates. The Firm shall not be liable for any direct or indirect damages, including lost profits, arising in any way from use of all or any of the information contained in its research communications. Northland may have issued other reports or documents that are inconsistent with and reach different conclusions from, the information contained in its research communications. Those documents reflect the different assumptions, views and analytical methods of the individuals who prepared them.
Northland’s research communications are produced in accordance with UK laws and regulations and its communications are not directed at or otherwise intended for any person whose nationality or residence may render receipt of such communications unlawful or in breach of any relevant regulations. Northland’s research communications are for the use of: (a) Professional Clients and ‘Institutions’ (such terms as defined in the FCA Rules); (b) other persons who have expressed interest in receiving communications and who are investment professionals (persons having professional experience in matters relating to investments, as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended)); and (c) any other persons to whom communications for the purposes of section 21 of the Financial Services and Markets Act 2000 can otherwise lawfully be communicated. Northland’s research communications may not be re-distributed, retransmitted or disclosed, in whole or in part, or in any manner, without the prior express written consent of Northland.
© Northland Capital Partners Limited 2015
